The Proper Ki-67 Cut-Off in Hormone Responsive Breast Cancer: A Monoinstitutional Analysis with Long-Term Follow-Up
Augusto Lombardi, Rachele Lazzeroni, Laura Bersigotti, Valeria Vitale, Claudio Amanti Department of Breast Surgery, Università di Roma La Sapienza – OspedaleSant’Andrea, Rome, ItalyCorrespondence: Laura BersigottiOspedaleSant’Andrea, via di Grottarossa 1035,...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2021-04-01
|
| Series: | Breast Cancer: Targets and Therapy |
| Subjects: | |
| Online Access: | https://www.dovepress.com/the-proper-ki-67-cut-off-in-hormone-responsive-breast-cancer-a-monoins-peer-reviewed-article-BCTT |
| _version_ | 1818572916276592640 |
|---|---|
| author | Lombardi A Lazzeroni R Bersigotti L Vitale V Amanti C |
| author_facet | Lombardi A Lazzeroni R Bersigotti L Vitale V Amanti C |
| author_sort | Lombardi A |
| collection | DOAJ |
| description | Augusto Lombardi, Rachele Lazzeroni, Laura Bersigotti, Valeria Vitale, Claudio Amanti Department of Breast Surgery, Università di Roma La Sapienza – OspedaleSant’Andrea, Rome, ItalyCorrespondence: Laura BersigottiOspedaleSant’Andrea, via di Grottarossa 1035, Rome, 00189, ItalyTel +39 3332559243Fax +39 06 33775649Email laufeberj@hotmail.itIntroduction: Breast cancer is a heterogeneous disease. Our study focuses on a monoinstitutional series of patients affected by Hormone Responsive carcinomas (luminal A and luminal B) and aims to define an optimal Ki-67 cut-off, to correctly stratify these patients into risk classes, using the ImmunoHistoChemical (IHC) surrogates of the Molecular Subtypes, according to the St. Gallen guidelines.Methods: We analyzed 1685 patients. These patients underwent both radical and conservative surgeries with Sentinel Lymph Node Biopsy eventually followed by Axillary Dissection (AD). Furthermore, all the patients underwent adjuvant therapies according to the guidelines. A retrospective univariate analysis was performed and survival curves (Disease-Related Survival, DRS, and Disease-Free Survival, DFS) were carried out according to the following ki-67 risk classes: Low Risk (Ki-67 ≤ 14%); Intermediate Risk (Ki-67 15% ÷ 20%); High Risk (Ki-67 > 20%).Results: 14 yy DRS was 98% in LA and 85% in LB with a ki-67 cut-off of 14% (p=0.037) vs 95% (LA) and 83% (LB) with a ki-67 cut-off of 20% (p=0.003). 14yy DFS was 85% in LA and 72% in LB with a ki-67 cut-off of 14% (p=0.017) vs 83% (LA) and 66% (LB) with a ki-67 cut-off of 20% (p< 0.000).Discussion: Our results confirmed that the 20% Ki-67 cut-off is more reliable in differentiating patients at low or high risk of recurrence and death, and stratifying patients eligible for adjuvant chemotherapy. Thus, despite its poor reproducibility, the identification of the most accurate ki-67 index assumes a pivotal relevance in guiding a tailored strategy among patients with this specific profile of breast cancer, as well as the molecular surrogates, in order to avoid harmful overtreatments.Keywords: Ki67, molecular subtypes, immunohistochemistry |
| first_indexed | 2024-12-15T00:04:02Z |
| format | Article |
| id | doaj.art-208262ef2da744348379312eb56dacc9 |
| institution | Directory Open Access Journal |
| issn | 1179-1314 |
| language | English |
| last_indexed | 2024-12-15T00:04:02Z |
| publishDate | 2021-04-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Breast Cancer: Targets and Therapy |
| spelling | doaj.art-208262ef2da744348379312eb56dacc92022-12-21T22:42:47ZengDove Medical PressBreast Cancer: Targets and Therapy1179-13142021-04-01Volume 1321321763716The Proper Ki-67 Cut-Off in Hormone Responsive Breast Cancer: A Monoinstitutional Analysis with Long-Term Follow-UpLombardi ALazzeroni RBersigotti LVitale VAmanti CAugusto Lombardi, Rachele Lazzeroni, Laura Bersigotti, Valeria Vitale, Claudio Amanti Department of Breast Surgery, Università di Roma La Sapienza – OspedaleSant’Andrea, Rome, ItalyCorrespondence: Laura BersigottiOspedaleSant’Andrea, via di Grottarossa 1035, Rome, 00189, ItalyTel +39 3332559243Fax +39 06 33775649Email laufeberj@hotmail.itIntroduction: Breast cancer is a heterogeneous disease. Our study focuses on a monoinstitutional series of patients affected by Hormone Responsive carcinomas (luminal A and luminal B) and aims to define an optimal Ki-67 cut-off, to correctly stratify these patients into risk classes, using the ImmunoHistoChemical (IHC) surrogates of the Molecular Subtypes, according to the St. Gallen guidelines.Methods: We analyzed 1685 patients. These patients underwent both radical and conservative surgeries with Sentinel Lymph Node Biopsy eventually followed by Axillary Dissection (AD). Furthermore, all the patients underwent adjuvant therapies according to the guidelines. A retrospective univariate analysis was performed and survival curves (Disease-Related Survival, DRS, and Disease-Free Survival, DFS) were carried out according to the following ki-67 risk classes: Low Risk (Ki-67 ≤ 14%); Intermediate Risk (Ki-67 15% ÷ 20%); High Risk (Ki-67 > 20%).Results: 14 yy DRS was 98% in LA and 85% in LB with a ki-67 cut-off of 14% (p=0.037) vs 95% (LA) and 83% (LB) with a ki-67 cut-off of 20% (p=0.003). 14yy DFS was 85% in LA and 72% in LB with a ki-67 cut-off of 14% (p=0.017) vs 83% (LA) and 66% (LB) with a ki-67 cut-off of 20% (p< 0.000).Discussion: Our results confirmed that the 20% Ki-67 cut-off is more reliable in differentiating patients at low or high risk of recurrence and death, and stratifying patients eligible for adjuvant chemotherapy. Thus, despite its poor reproducibility, the identification of the most accurate ki-67 index assumes a pivotal relevance in guiding a tailored strategy among patients with this specific profile of breast cancer, as well as the molecular surrogates, in order to avoid harmful overtreatments.Keywords: Ki67, molecular subtypes, immunohistochemistryhttps://www.dovepress.com/the-proper-ki-67-cut-off-in-hormone-responsive-breast-cancer-a-monoins-peer-reviewed-article-BCTTki67molecular subtypesimmunohistochemistry |
| spellingShingle | Lombardi A Lazzeroni R Bersigotti L Vitale V Amanti C The Proper Ki-67 Cut-Off in Hormone Responsive Breast Cancer: A Monoinstitutional Analysis with Long-Term Follow-Up Breast Cancer: Targets and Therapy ki67 molecular subtypes immunohistochemistry |
| title | The Proper Ki-67 Cut-Off in Hormone Responsive Breast Cancer: A Monoinstitutional Analysis with Long-Term Follow-Up |
| title_full | The Proper Ki-67 Cut-Off in Hormone Responsive Breast Cancer: A Monoinstitutional Analysis with Long-Term Follow-Up |
| title_fullStr | The Proper Ki-67 Cut-Off in Hormone Responsive Breast Cancer: A Monoinstitutional Analysis with Long-Term Follow-Up |
| title_full_unstemmed | The Proper Ki-67 Cut-Off in Hormone Responsive Breast Cancer: A Monoinstitutional Analysis with Long-Term Follow-Up |
| title_short | The Proper Ki-67 Cut-Off in Hormone Responsive Breast Cancer: A Monoinstitutional Analysis with Long-Term Follow-Up |
| title_sort | proper ki 67 cut off in hormone responsive breast cancer a monoinstitutional analysis with long term follow up |
| topic | ki67 molecular subtypes immunohistochemistry |
| url | https://www.dovepress.com/the-proper-ki-67-cut-off-in-hormone-responsive-breast-cancer-a-monoins-peer-reviewed-article-BCTT |
| work_keys_str_mv | AT lombardia theproperki67cutoffinhormoneresponsivebreastcanceramonoinstitutionalanalysiswithlongtermfollowup AT lazzeronir theproperki67cutoffinhormoneresponsivebreastcanceramonoinstitutionalanalysiswithlongtermfollowup AT bersigottil theproperki67cutoffinhormoneresponsivebreastcanceramonoinstitutionalanalysiswithlongtermfollowup AT vitalev theproperki67cutoffinhormoneresponsivebreastcanceramonoinstitutionalanalysiswithlongtermfollowup AT amantic theproperki67cutoffinhormoneresponsivebreastcanceramonoinstitutionalanalysiswithlongtermfollowup AT lombardia properki67cutoffinhormoneresponsivebreastcanceramonoinstitutionalanalysiswithlongtermfollowup AT lazzeronir properki67cutoffinhormoneresponsivebreastcanceramonoinstitutionalanalysiswithlongtermfollowup AT bersigottil properki67cutoffinhormoneresponsivebreastcanceramonoinstitutionalanalysiswithlongtermfollowup AT vitalev properki67cutoffinhormoneresponsivebreastcanceramonoinstitutionalanalysiswithlongtermfollowup AT amantic properki67cutoffinhormoneresponsivebreastcanceramonoinstitutionalanalysiswithlongtermfollowup |